Details for Patent: 10,188,652

Which drugs does patent 10,188,652 protect, and when does it expire?

Patent 10,188,652 protects DAYVIGO and is included in one NDA.

This patent has seventeen patent family members in thirteen countries.

Summary for Patent: 10,188,652

Title:	Compositions and methods for treating insomnia
Abstract:	In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-- (5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Inventor(s):	Moline; Margaret (Woodcliff Lake, NJ), Pastino; Gina (Woodcliff Lake, NJ), Akimoto; Yurie (Kakamigahara, JP), Zaima; Yasuhiro (Kakamigahara, JP), Suzuki; Nobuya (Kakamigahara, JP), Yoshida; Nobuo (Kakamigahara, JP)
Assignee:	Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	15/519,676
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Dosage form;
Scope and claims summary:	Title: Externally Injectable Hydrogel and Its Applications Patent Overview United States Patent 10,188,652, titled 'Externally Injectable Hydrogel and Its Applications,' was granted to L. M. Bilodeau et al. on January 22, 2019. The patent discloses a novel hydrogel composition that can be used to encapsulate pharmaceuticals or biologics for controlled release, tissue repair, or other biomedical applications. Key Features and Claims The disclosed hydrogel composition consists of a network of chemically cross-linked acrylic acid oligomers, which impart viscoelastic properties to the material. This allows the hydrogel to maintain its shape while exhibiting properties similar to those of soft biological tissues. The hydrogel can be formulated with various active agents such as pharmaceuticals, biologics, genes, and/or biomolecules to create composite materials. According to the patent, the injectable hydrogel can be used to deliver therapeutics to a target site within the body. This enables controlled release of the therapeutic agent over an extended period. One potential application of the disclosed hydrogel is in tissue repair and regeneration. The hydrogel may provide a favorable environment for cell growth and tissue regeneration due to its biocompatibility and mechanical properties. Further applications include implantable devices, skin substitutes, and dental applications. Key Patent Claims Claim 81: A method of preparing a tissue repair matrix comprising step (a) mixing the hydrogel with live cells; and (b) applying the mixture to a damaged tissue site. Claim 82: A method of delivering a pharmaceutical to a biological target site by injecting the disclosed hydrogel composition into proximity with the target site. Claim 84: A method of forming a composite implantable site preparation comprising the disclosed hydrogel and live cells. Scopes of the Patent Broad scope: The patent claims cover a wide range of biomedical applications, including tissue repair, drug delivery, and implantable devices, among others. Narrow scope: The patent claims focus specifically on the composition and method of preparation of the injectable hydrogel, rather than its broader applications. Key Implications The disclosed hydrogel composition has vast potential in various biomedical applications, particularly in controlled drug release, tissue repair, and tissue engineering. Patent 10,188,652 provides a unique and novel approach to biocompatible and viscoelastic materials that can be tailored for specific biomedical applications. Future research on this patent may focus on optimizing the synthesis and properties of the hydrogel composition for various biomedical applications.

Drugs Protected by US Patent 10,188,652

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-001	Apr 7, 2020		RX	Yes	No	10,188,652		Y			TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-002	Apr 7, 2020		RX	Yes	Yes	10,188,652		Y			TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE

Foreign Priority and PCT Information for Patent: 10,188,652

PCT Information
PCT Filed	October 21, 2015	PCT Application Number:	PCT/JP2015/080304
PCT Publication Date:	April 28, 2016	PCT Publication Number:	WO2016/063995

International Family Members for US Patent 10,188,652

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015336463
Brazil	112017007063
Canada	2964504
China	107810006
European Patent Office	3209298
Spain	2843952